Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.

PURPOSE: Due to the excellent outcomes with image-guided stereotactic body radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) and the low treatment-related toxicities using proton therapy (PT), we investigated treatment outcomes and toxicities when delivering hypofractionated PT. MATERIALS AND METHODS: Between 2009 and 2018, 22 patients with T1 to T2 N0M0 NSCLC (45% T1, 55% T2) received image-guided hypofractionated PT. The median age at diagnosis was 72 years (range, 58-90). Patients underwent 4-dimensional computed tomography simulation following fiducial marker placement, and daily image guidance was performed. Nine patients (41%) were treated with 48 GyRBE in 4 fractions for peripheral lesions, and 13 patients (59%) were treated with 60 GyRBE in 10 fractions for central lesions. Patients were assessed for CTCAEv4 toxicities with computed tomography imaging for tumor assessment. The primary endpoint was grade 3 to 5 toxicity at 1 year. RESULTS: The median follow-up for all patients was 3.5 years (range, 0.2-8.8 years). The overall survival rates at 3 and 5 years were 81% and 49%, respectively. Cause-specific survival rates at 3 and 5 years were 100% and 75%, respectively. The 3-year local, regional, and distant control rates were 86%, 85%, and 95%, respectively. Four patients experienced in-field recurrences between 18 and 45 months after treatment. One patient (5%) developed a late grade 3 bronchial stricture requiring hospitalization and stent. CONCLUSION: Image-guided hypofractionated PT for early-stage NSCLC provides promising local control and long-term survival with a low likelihood of toxicity. Regional nodal and distant relapses remain a problem.

Physical validation of UF-RIPSA: A rapid in-clinic peak skin dose mapping algorithm for fluoroscopically guided interventions.

PURPOSE: The purpose of this study was to experimentally validate UF-RIPSA, a rapid in-clinic peak skin dose mapping algorithm developed at the University of Florida using optically stimulated luminescent dosimeters (OSLDs) and tissue-equivalent phantoms. METHODS: The OSLDs used in this study were InLightTM Nanodot dosimeters by Landauer, Inc. The OSLDs were exposed to nine different beam qualities while either free-in-air or on the surface of a tissue equivalent phantom. The irradiation of the OSLDs was then modeled using Monte Carlo techniques to derive correction factors between free-in-air exposures and more complex irradiation geometries. A grid of OSLDs on the surface of a tissue equivalent phantom was irradiated with two fluoroscopic x ray fields generated by the Siemens Artis zee bi-plane fluoroscopic unit. The location of each OSLD within the grid was noted and its dose reading compared with UF-RIPSA results. RESULTS: With the use of Monte Carlo correction factors, the OSLD's response under complex irradiation geometries can be predicted from its free-in-air response. The predicted values had a percent error of -8.7% to +3.2% with a predicted value that was on average 5% below the measured value. Agreement within 9% was observed between the values of the OSLDs and RIPSA when irradiated directly on the phantom and within 14% when the beam first traverses the tabletop and pad. CONCLUSIONS: The UF-RIPSA only computes dose values to areas of irradiated skin determined to be directly within the x ray field since the algorithm is based upon ray tracing of the reported reference air kerma value, with subsequent corrections for air-to-tissue dose conversion, x ray backscatter, and table/pad attenuation. The UF-RIPSA algorithm thus does not include the dose contribution of scatter radiation from adjacent fields. Despite this limitation, UF-RIPSA is shown to be fairly robust when computing skin dose to patients undergoing fluoroscopically guided interventions.

A hybrid phantom system for patient skin and organ dosimetry in fluoroscopically guided interventions.

PURPOSE: The purpose of this study was to investigate calibrations for improved estimates of skin dose and to develop software for computing absorbed organ doses for fluoroscopically guided interventions (FGIs) with the use of radiation dose structured reports (RDSR) and the UF/NCI family of hybrid computational phantoms. METHODS AND MATERIALS: Institutional review board approval was obtained for this retrospective study in which ten RDSRs were selected for their high cumulative reference air kerma values. Skin doses were computed using the University of Florida's rapid in-clinic peak skin dose algorithm (or UF-RIPSA). Kerma-area product (KAP) meter calibrations and attenuation of the tabletop with pad were incorporated into the UF-RIPSA. To compute absorbed organ doses the RDSRs were coupled with software to develop Monte Carlo input decks for each irradiation event. The effects of spectrum matching were explored by modeling (a) a polychromatic x-ray energy beam made to match measured first half-value layers of aluminum, (b) an unmatched spectrum, (c) and a mono-energetic beam equivalent to the effective x-ray energy. The authors also considered the practicality of computing organ doses for each irradiation event within a RDSR. RESULTS: The KAP meter is highly dependent on the quality of the x-ray spectra. Monte Carlo based attenuation coefficients for configurations in which the beam is transmitted through the tabletop with pad reduced the amount by which the software overestimated skin doses. For absorbed organ dose computations, the average ratios of computed organ doses for a non-fitted to fitted spectrum and effective energy to fitted spectrum were 0.45 and 0.03, respectively. Monte Carlo simulations on average took 38 min per patient. All in-field organ tallies converged with a relative error of less than 1% and out-of-field organs tallies within 10% relative error. CONCLUSIONS: This work details changes to the UF-RIPSA software that include an expanded library of computational phantoms, attenuation coefficients for tabletop with pad, and calibration curves for the KAP meter. For the computation of absorbed organ dose, it is possible to model each irradiation event separately on a patient-dependent model that best morphometrically matches the patient, thus providing a full report of internal organ doses for FGI patients.

Preoperative Protective Endovascular Covered Stent Placement Followed by Surgery for Management of the Cervical Common and Internal Carotid Arteries with Tumor Encasement.

Objective The objective of this study was to report the outcomes on a preliminary cohort of patients with tumor encasement of either, or both, the cervical internal carotid artery (ICA) and common carotid artery (CCA) following preoperative covered stent placement and surgical resection. Setting This study was set at the University of Florida College of Medicine, Jacksonville, FL. Participants Subjects who received preoperative stenting of the cervical ICA/CCA before surgical resection of head and neck tumors between April 1, 2015, and July 31, 2015 were participated. Main Outcome Measures The outcomes assessed were resectability of tumors after stenting, histopathological assessment of specimen margins, complications associated with stenting. Results Five subjects received preoperative covered stent placement of the ICA/CCA before surgical resection. The mean age was 65.2 years. Median follow-up was 3.5 months. Excision of the adventitia from the stent was performed in all subjects. No intraoperative complications occurred. One vascular-related complication occurred in one subject who suffered occlusion of the stent, sustaining a ministroke. No involvement of tumor at the deep margin (inner surface of adventitia) of the resection was seen in any subjects. Conclusions Preoperative covered stent placement of the cervical ICA/CCA in the management of subjects with head and neck tumors who display encasement on preoperative imaging may represent a safe and effective treatment.